IRCT20090117001556N127尚未招募2 期
Palmitoylethanolamide as adjuvant therapy in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double blind and placebo controlled clinical trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Age between 18 to 60 years
- •Take Risperidone for at least 4 weeks at the dose of 4-6 mg/day before entering the study
- •The positive and acute symptoms of patients should be stable
排除标准
- •Head trauma
- •History of shock therapy during past three months prior to the trial
- •Undergoing neurosurgery
- •Presence of acute or chronic systemic diseases
- •History of allergy to Cilostazol
研究者
相似试验
招募中
不适用
Palmitoylethanolamide in the treatment of major depressioMajor Depressive Disorder.Major Depressive DisorderIRCT201702181556N97Tehran University of Medical Sciences50
招募中
不适用
Palmitoylethanolamide as adjunctive treatment of Autism: A double blind and placebo controlled trialChildhood autism.Childhood autismIRCT201702171556N96Tehran University of Medical Sciences50
已完成
不适用
Can muscle growth and strength gains from weight training in young, active, healthy adults be affected by supplementing with palmitoylethanolamide?Skeletal muscleMusculoskeletal - Normal musculoskeletal and cartilage development and functionACTRN12621001726842Deakin University50
招募中
2 期
The effect of Palmitoylethanolamide on the treatment of maniaBipolar disorderIRCT20090117001556N135Tehran University of Medical Sciences50
尚未招募
4 期
Palmitoylethanolamide for the treatment of centralised chronic paiChronic PainAnaesthesiology - Pain managementACTRN12619000418178Daniel Ellyard100